Open label study to assess efficacy and safety of the fully human anti tumour necrosis factor alpha monoclonal antibody adalimumab

Trial Profile

Open label study to assess efficacy and safety of the fully human anti tumour necrosis factor alpha monoclonal antibody adalimumab

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Adalimumab; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PROWD
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 23 Jun 2016 Results of safety analysis of this and other trials published in the Annals of the Rheumatic Diseases.
    • 13 Jun 2009 Results were reported at the 2009 EULAR.
    • 16 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top